西安出台生物医药产业提升方案，力争到2027年产业规模达到400亿元【附生物医药行业市场分析】

Core Insights - The Xi'an municipal government has issued a plan to enhance the biopharmaceutical industry, aiming for a scale of 40 billion yuan by 2027, with specific targets for traditional Chinese medicine, chemical drugs, biopharmaceuticals, medical devices, and consumer healthcare [2][3] - The biopharmaceutical industry in Xi'an has a rich history of nearly 90 years and is a key manufacturing and R&D base in Northwest China, with a 2022 output value of 29 billion yuan [2][3] - The central government has prioritized the biopharmaceutical industry as a strategic emerging industry, essential for national security and economic development, positioning it alongside other advanced technologies in future economic growth [3][4] Industry Overview - By the end of 2022, Xi'an High-tech Zone housed 4,120 biopharmaceutical companies and 9 listed firms, with an industry scale exceeding 60 billion yuan, making it a leading area in the central and western regions of China [2] - The industry has developed a comprehensive structure, including chemical drugs, biopharmaceuticals, traditional Chinese medicine, and medical devices, with notable companies like Xi'an Janssen and Giant Bio [2][3] - China's pharmaceutical manufacturing revenue for regulated enterprises was 2.95 trillion yuan in 2023, showing a recovery trend after a decline from 2015 to 2023 [3][4] Future Projections - The biopharmaceutical industry is expected to grow significantly, with projections indicating that revenue for regulated pharmaceutical enterprises will reach 5.4 trillion yuan by 2029, with an average annual growth rate of 14.04% from 2024 to 2029 [4] - Experts recommend leveraging the advantages of a new national system to strengthen the biopharmaceutical industry through top-level design, industrial layout, and innovation ecosystems [7]